Table 1.
In vitro cytotoxicity of nemorosone in neuroblastoma and fibroblasts cell lines. Cytotoxicity of nemorosone over 24 hrs in a panel of tumour (both parental and chemotherapy refractory) and non-tumour cell lines as assessed by Sulforhodamine B (SRB) assay. Values represent the means ± standard deviation of at least three independent experiments. R F, resistance factor: (IC50 resistant/ IC50 parental). Parental and chemotherapy refractory sub-lines were employed. (MDR1: multi-drug resistance 1, was determined by FACS and represented in %) No cross-resistance was observed. Fibroblasts were less sensitive to nemorosone.
| Cell Lines | Histology | Resistant against | Resistance factor | IC50 nemorosone (μM) |
|---|---|---|---|---|
| LAN-1* | Neuroblastoma | - | 1 | 4.10 ± 0.28 |
| MDR1- | ||||
| LAN-1 CP* | Neuroblastoma | Cisplatinum | 32 | 4. 22 ± 0.26 |
| LAN-1 ETO* | Neuroblastoma | Etoposide | 128 | 4.99 ± 0.22 |
| >99 % MDR1+ | ||||
| LAN-1 ADR* | Neuroblastoma | Adriamycin | 128 | 4.92 ± 0.36 |
| >99 % MDR1+ | ||||
| LAN-1 5FU* | Neuroblastoma | 5-fluorouracil | 64 | 4.12 ± 0.31 |
| NB69** | Neuroblastoma | - | 1 | 3.10 ± 0.15 |
| Kelly* | Neuroblastoma | - | 1 | 5.2 ± 0.42 |
| SK-N-AS** | Neuroblastoma | - | 1 | 6.3 ± 0.21 |
| NIH-3T3 | Mouse fibroblasts | - | 1 | >21.00 |
| MRC-5 | Human embryonic fibroblasts | - | 1 | >40.00 |
*
Cells with MYCN amplification,
**
Cells without MYCN amplification